Baldwin Investment Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.07M | Buy |
44,312
+7,914
| +22% | +$207K | 0.1% | 111 |
|
|
2026
Q1 | $1.02M | Sell |
36,398
-2,050
| -5% | -$54.6K | 0.12% | 99 |
|
|
2025
Q4 | $957K | Sell |
38,448
-15,190
| -28% | -$383K | 0.11% | 114 |
|
|
2025
Q3 | $1.37M | Buy |
53,638
+400
| +0.8% | +$9.87K | 0.16% | 79 |
|
|
2025
Q2 | $1.29M | Buy |
53,238
+7,320
| +16% | +$171K | 0.16% | 85 |
|
|
2025
Q1 | $1.16M | Buy |
45,918
+27,940
| +155% | +$731K | 0.14% | 90 |
|
|
2024
Q4 | $477K | Sell |
17,978
-2,320
| -11% | -$62.9K | 0.06% | 156 |
|
|
2024
Q3 | $587K | Buy |
20,298
+5,875
| +41% | +$171K | 0.07% | 145 |
|
|
2024
Q2 | $404K | Buy |
14,423
+100
| +0.7% | +$2.75K | 0.06% | 161 |
|
|
2024
Q1 | $397K | Sell |
14,323
-1,125
| -7% | -$31.2K | 0.05% | 164 |
|
|
2023
Q4 | $445K | Sell |
15,448
-300
| -2% | -$9.07K | 0.07% | 146 |
|
|
2023
Q3 | $522K | Sell |
15,748
-1,928
| -11% | -$68.2K | 0.09% | 132 |
|
|
2023
Q2 | $648K | Sell |
17,676
-400
| -2% | -$15.6K | 0.11% | 125 |
|
|
2023
Q1 | $738K | Buy |
18,076
+147
| +0.8% | +$6.35K | 0.13% | 113 |
|
|
2022
Q4 | $919K | Sell |
17,929
-50
| -0.3% | -$2.4K | 0.17% | 92 |
|
|
2022
Q3 | $787K | Hold |
17,979
| – | – | 0.16% | 99 |
|
|
2022
Q2 | $943K | Hold |
17,979
| – | – | 0.18% | 96 |
|
|
2022
Q1 | $931K | Sell |
17,979
-600
| -3% | -$31.1K | 0.14% | 109 |
|
|
2021
Q4 | $1.1M | Sell |
18,579
-300
| -2% | -$14.9K | 0.17% | 96 |
|
|
2021
Q3 | $812K | Hold |
18,879
| – | – | 0.14% | 112 |
|
|
2021
Q2 | $739K | Sell |
18,879
-3,925
| -17% | -$153K | 0.13% | 118 |
|
|
2021
Q1 | $826K | Sell |
22,804
-12,185
| -35% | -$433K | 0.15% | 114 |
|
|
2020
Q4 | $1.29M | Sell |
34,989
-282
| -0.8% | -$10.3K | 0.25% | 73 |
|
|
2020
Q3 | $1.23M | Buy |
35,271
+27,705
| +366% | +$971K | 0.29% | 60 |
|
|
2020
Q2 | $235K | Buy |
7,566
+448
| +6% | +$15.2K | 0.07% | 141 |
|
|
2020
Q1 | $220K | Sell |
7,118
-131
| -2% | -$4.46K | 0.08% | 134 |
|
|
2019
Q4 | $269K | Sell |
7,249
-211
| -3% | -$7.52K | 0.07% | 147 |
|
|
2019
Q3 | $254K | Hold |
7,460
| – | – | 0.07% | 145 |
|
|
2019
Q2 | $307K | Sell |
7,460
-106
| -1% | -$4.21K | 0.09% | 135 |
|
|
2019
Q1 | $305K | Hold |
7,566
| – | – | 0.09% | 133 |
|
|
2018
Q4 | $313K | Sell |
7,566
-263
| -3% | -$10.9K | 0.1% | 126 |
|
|
2018
Q3 | $327K | Sell |
7,829
-843
| -10% | -$32.5K | 0.09% | 131 |
|
|
2018
Q2 | $299K | Buy |
+8,672
| New | +$296K | 0.09% | 141 |
|
Other funds holding PFE
Baldwin Investment Management's PFE Position: Q2 2026 in Review
Baldwin Investment Management increased its Pfizer (PFE) stake by 22% in Q2 2026, buying an estimated $207K and bringing the position to 44,312 shares worth $1.07M. The position accounts for 0.1% of the portfolio, ranked #111.
Baldwin Investment Management first reported a position in PFE in Q2 2018 and has held it in 33 quarters since. The position peaked at $1.37M in Q3 2025. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Baldwin Investment Management held 44,312 shares of Pfizer worth $1.07M as of Q2 2026.
- Baldwin Investment Management bought 7,914 Pfizer shares in Q2 2026, an estimated $207K.
- Pfizer made up 0.1% of Baldwin Investment Management's portfolio in Q2 2026, its #111 holding.
- Baldwin Investment Management first reported a position in Pfizer in Q2 2018 and has held it in 33 quarters since.
- Baldwin Investment Management's Pfizer position peaked at $1.37M in Q3 2025.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Baldwin Investment Management's 13F filing for Q2 2026, filed 28 Jul 2026.